Dr. Allison has received financial and other benefits from the following entities: the Frontiers Foundation; Arnold Foundation; Templeton Foundation; NIH, NSF, USDA, The State of Oregon Department of Justice, The Federal Trade Commission; The FDA; The Nutrition Science Initiative (NUSI), IKEA; Law Offices of Ronald Marron; Paul Hastings, LLP; Tomasik, Kotin & Kasserman LLC., WW (formerly Weight Watchers) and numerous additional government, non-profit and for-profit (including litigation, publishing, food, beverage, dietary supplement, commodity, and pharmaceutical) organizations with interests in research, obesity, nutrition, and health.
Dr. Ard reports personal fees from Novo Nordisk, Amgen, Boehringer-Ingelheim, grants and personal fees from Nestle Healthcare Nutrition, and non-financial support from Vivus, Inc.
Dr. Aronne has served as a consultant for Amgen, Allurion, Aspire Bariatrics, Eisai, Janssen, Novo Nordisk, Pfizer, Zafgen Inc.
Dr. Aronne is CEO of BMIQ. Dr. Aronne has ownership interest in Myos Corporation, Zafgen, Inc., Gelesis, and ERX.
Dr. Aronne serves on the Board of Directors for Myos Corporation, Jamieson Laboratories.
Dr. Busetto reports personal fees from Novo Nordisk and Bruno Farmaceutici, and grants from Enzym Management.
Dr. Kelly serves as a consultant for Novo Nordisk, Vivus, and WW, does not accept personal or professional income for these activities.
Dr. Kelly has a drug/placebo provision from Astra Zeneca for an NIDDK-funded clinical trial for which he is the Primary Investigator.
Dr. Mechanick has received honoraria for lectures from Abbott Nutrition International.
Dr. Mechanick serves on the board of directors for the American Association of Clinical Endocrinologists (AACE).
Dr. Mechanick is co-chair of the Physician Engagement Committee for American Society for Parenteral and Enteral Nutrition (ASPEN).
Dr. Mechanick is Medical Director, Kravis Center Cardiovascular Health.
Dr. Purnell receives compensation for Global Advisory Board consulting for Novo Nordisk.